Novavax, Inc.: Novavax Announces Extended Durability of Protection Against Infection and Disease in United Kingdom COVID-19 Vaccine Phase 3 Clinical Trial

- NVX-CoV2373 demonstrates protection against symptomatic and asymptomatic infection - High level of vaccine efficacy maintained over a 6-month period of surveillance - Continued

Related Keywords

United Kingdom ,India ,Laura Keenan Lindsey ,Erika Schultz ,Gregorym Glenn ,Alexandra Roy ,Ali Chartan ,Linkedin ,World Health Organization ,European Commission ,Prnewswire Novavax Inc ,Nasdaq ,Exchange Commission ,Serum Institute Of India ,Novavax Inc ,United Kingdom Phase ,New England Journal ,Serum Institute ,World Health ,Financial Condition ,Novavax Annual Report ,Quarterly Reports ,Keenan Lindsey ,Novavax ,Nnounces ,Xtended ,Durability ,Protection ,Against ,Infection ,Disease ,United ,Kingdom ,Covid ,Vaccine ,Hase ,Linical ,Trial ,